You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tremelimumab

Showing 26 - 50 of 105
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced and/or Metastatic Sarcoma Trial in Houston (Durvalumab, Tremelimumab)

Active, not recruiting
  • Advanced and/or Metastatic Sarcoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 7, 2022

Germ Cell Tumor, Nonseminomatous Germ Cell Tumor, Seminoma Trial in United States (Durvalumab, Tremelimumab)

Active, not recruiting
  • Germ Cell Tumor
  • +5 more
  • Basking Ridge, New Jersey
  • +6 more
May 2, 2022

Metastatic or Locally Advanced NSCLC Trial in Ramat Gan (Durvalumab, Tremelimumab, Low dose irradiation)

Recruiting
  • Metastatic or Locally Advanced NSCLC
  • Ramat Gan, Israel
    Sheba Medical Centre
Jan 9, 2022

Biliary Tract Tumors Trial in Seoul (Durvalumab, Tremelimumab, Gemcitabine)

Active, not recruiting
  • Biliary Tract Neoplasms
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Oct 26, 2021

Squamous NSCLC, Non-Squamous NSCLC Trial (Durvalumab, Tremelimumab)

Withdrawn
  • Squamous Non-small Cell Lung Cancer
  • Non-Squamous Non-small Cell Lung Cancer
  • (no location specified)
Dec 17, 2021

Infiltrating Bladder Urothelial Carcinoma Trial in France (Durvalumab, Tremelimumab, MVAC Protocol)

Recruiting
  • Infiltrating Bladder Urothelial Carcinoma
  • Paris, Ile De France, France
  • +14 more
Apr 21, 2022

Colorectal Cancer Metastatic Trial in United States (durvalumab, Tremelimumab)

Completed
Has Results
  • Colorectal Cancer Metastatic
  • Duarte, California
  • +17 more
Nov 8, 2022

Advanced Hepatocellular Carcinoma Trial in Worldwide (Durvalumab, Tremelimumab)

Not yet recruiting
  • Advanced Hepatocellular Carcinoma
  • La Jolla, California
  • +46 more
May 22, 2023

Invasive Bladder Cancer Trial in Spain (Durvalumab, Tremelimumab, Radiotherapy)

Active, not recruiting
  • Invasive Bladder Cancer
  • Badalona, Barcelona, Spain
  • +6 more
Mar 9, 2022

Hepatocellular Carcinoma Trial (Livmoniplimab, Budigalimab, Durvalumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • (no location specified)
Oct 26, 2023

Mesothelioma, Malignant Trial in Toronto (Cyclophosphamide, Tremelimumab, Durvalumab)

Recruiting
  • Mesothelioma, Malignant
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
May 13, 2022

Urothelial Carcinoma Trial in United States (Tremelimumab)

Active, not recruiting
  • Urothelial Carcinoma
  • Tremelimumab
  • Washington, District of Columbia
  • +6 more
Feb 24, 2022

Esophageal Adenocarcinoma Trial in Cologne, München (Durvalumab 50 MG/ML, Tremelimumab)

Recruiting
  • Esophageal Adenocarcinoma
  • Durvalumab 50 MG/ML
  • Tremelimumab
  • Cologne, Germany
  • +1 more
Feb 17, 2022

Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma Trial in Frankfurt am Main (Durvalumab,

Recruiting
  • Biliary Tract Cancer (CCA)
  • +4 more
  • Frankfurt am Main, Germany
    Krankenhaus Nordwest
Jun 23, 2022

Intrahepatic Cholangiocarcinoma Trial in Germany (Durvalumab, Tremelimumab)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Dresden, Germany
  • +7 more
Apr 13, 2022

Bladder Cancer Trial in Spain (Durvalumab, Tremelimumab, Cisplatin-based neoadjuvant chemo)

Active, not recruiting
  • Bladder Cancer
  • Badalona, Spain
  • +10 more
Feb 8, 2022

Renal Clear Cell Carcinoma, Renal Papillary Cell Carcinoma Trial in London (Savolitinib, MEDI4736, Tremelimumab)

Active, not recruiting
  • Renal Clear Cell Carcinoma
  • Renal Papillary Cell Carcinoma
  • London, United Kingdom
    Thomas Powles
Aug 10, 2022

Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma Trial in Edmonton, London, Montréal (SBRT, Durvalumab,

Active, not recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Metastatic Squamous Cell Carcinoma
  • SBRT
  • +2 more
  • Edmonton, Alberta, Canada
  • +2 more
Mar 14, 2022

Hepatocellular Carcinoma Trial in Hong Kong (Durvalumab, Tremelimumab, Yttrium-90 radioembolisation)

Recruiting
  • Hepatocellular Carcinoma
  • Hong Kong, Hong Kong
    Department of Clinical Oncology, Queen Mary Hospital
Apr 10, 2023

Solid Malignancies Trial in Canada (durvalumab, tremelimumab)

Active, not recruiting
  • Solid Malignancies
  • Calgary, Alberta, Canada
  • +6 more
Jan 24, 2022

Cholangiocarcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma Non-resectable Trial in Hannover (Durvalumab, Gemcitabine,

Active, not recruiting
  • Cholangiocarcinoma
  • +3 more
  • Durvalumab
  • +3 more
  • Hannover, Germany
    Medizinische Hochschule Hannover, Klinik für Gastroenterologie,
Oct 14, 2021

Prostate Cancer Trial in Canada (Durvalumab, Tremelimumab)

Active, not recruiting
  • Prostate Cancer
  • Kelowna, British Columbia, Canada
  • +10 more
Mar 14, 2022

Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma Trial in United States (Durvalumab, Tremelimumab, Poly ICLC)

Completed
  • Head and Neck Squamous Cell Carcinoma
  • +10 more
  • Atlanta, Georgia
  • +6 more
Mar 1, 2022

Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer Trial in Spain

Recruiting
  • Metastatic Thyroid Papillary Carcinoma
  • +2 more
  • L'Hospitalet de Llobregat, Barcelona, Spain
  • +14 more
Feb 18, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma Trial in United

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • Orange, California
  • +15 more
Aug 23, 2022